TY - JOUR
T1 - Ovarian cancer, version 2.2020
AU - Armstrong, Deborah K.
AU - Alvarez, Ronald D.
AU - Bakkum-Gamez, Jamie N.
AU - Barroilhet, Lisa
AU - Behbakht, Kian
AU - Berchuck, Andrew
AU - Chen, Lee May
AU - Cristea, Mihaela
AU - DeRosa, Maria
AU - Eisenhauer, Eric L.
AU - Gershenson, David M.
AU - Gray, Heidi J.
AU - Grisham, Rachel
AU - Hakam, Ardeshir
AU - Jain, Angela
AU - Karam, Amer
AU - Konecny, Gottfried E.
AU - Leath, Charles A.
AU - Liu, Joyce
AU - Mahdi, Haider
AU - Martin, Lainie
AU - Matei, Daniela
AU - McHale, Michael
AU - McLean, Karen
AU - Miller, David S.
AU - O'Malley, David M.
AU - Percac-Lima, Sanja
AU - Ratner, Elena
AU - Remmenga, Steven W.
AU - Vargas, Roberto
AU - Werner, Theresa L.
AU - Zsiros, Emese
AU - Burns, Jennifer L.
AU - Engh, Anita M.
N1 - Publisher Copyright:
© 2021 Harborside Press. All rights reserved.
PY - 2021/2/2
Y1 - 2021/2/2
N2 - Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States and is the country's fifth most common cause of cancer mortality in women. A major challenge in treating ovarian cancer is that most patients have advanced disease at initial diagnosis. These NCCN Guidelines discuss cancers originating in the ovary, fallopian tube, or peritoneum, as these are all managed in a similar manner. Most of the recommendations are based on data from patients with the most common subtypes-high-grade serous and grade 2/3 endometrioid. The NCCN Guidelines also include recommendations specifically for patients with less common ovarian cancers, which in the guidelines include the following: Carcinosarcoma, clear cell carcinoma, mucinous carcinoma, low-grade serous, grade 1 endometrioid, borderline epithelial, malignant sex cordstromal, and malignant germ cell tumors. This manuscript focuses on certain aspects of primary treatment, including primary surgery, adjuvant therapy, and maintenance therapy options (including PARP inhibitors) after completion of first-line chemotherapy.
AB - Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States and is the country's fifth most common cause of cancer mortality in women. A major challenge in treating ovarian cancer is that most patients have advanced disease at initial diagnosis. These NCCN Guidelines discuss cancers originating in the ovary, fallopian tube, or peritoneum, as these are all managed in a similar manner. Most of the recommendations are based on data from patients with the most common subtypes-high-grade serous and grade 2/3 endometrioid. The NCCN Guidelines also include recommendations specifically for patients with less common ovarian cancers, which in the guidelines include the following: Carcinosarcoma, clear cell carcinoma, mucinous carcinoma, low-grade serous, grade 1 endometrioid, borderline epithelial, malignant sex cordstromal, and malignant germ cell tumors. This manuscript focuses on certain aspects of primary treatment, including primary surgery, adjuvant therapy, and maintenance therapy options (including PARP inhibitors) after completion of first-line chemotherapy.
KW - Adenocarcinoma, Clear Cell
KW - Carcinoma, Ovarian Epithelial/diagnosis
KW - Female
KW - Humans
KW - Ovarian Neoplasms/diagnosis
UR - http://www.scopus.com/inward/record.url?scp=85101062235&partnerID=8YFLogxK
U2 - 10.6004/jnccn.2021.0007
DO - 10.6004/jnccn.2021.0007
M3 - Article
C2 - 33545690
SN - 1540-1405
VL - 19
SP - 191
EP - 226
JO - Journal of the National Comprehensive Cancer Network : JNCCN
JF - Journal of the National Comprehensive Cancer Network : JNCCN
IS - 2
ER -
